Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $146,207.31 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 6,667 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $21.93, for a total value of $146,207.31. Following the completion of the transaction, the chief operating officer now directly owns 329,977 shares in the company, valued at $7,236,395.61. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Anish Patel also recently made the following trade(s):

• On Tuesday, January 7th, Anish Patel sold 21,700 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.18, for a total value of $524,706.00.

Enliven Therapeutics Trading Down 2.0 %

ELVN opened at $21.55 on Tuesday. The business has a 50 day moving average of $22.77 and a 200-day moving average of $24.23. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of -11.34 and a beta of 1.03. Enliven Therapeutics, Inc. has a 1-year low of $10.90 and a 1-year high of $30.03.

Hedge Funds Weigh In On Enliven Therapeutics

Large investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. grew its position in Enliven Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock worth $232,000 after purchasing an additional 3,559 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Enliven Therapeutics in the third quarter valued at about $256,000. Verition Fund Management LLC acquired a new stake in Enliven Therapeutics during the third quarter worth about $271,000. The Manufacturers Life Insurance Company bought a new position in Enliven Therapeutics during the second quarter valued at about $322,000. Finally, Quest Partners LLC raised its holdings in Enliven Therapeutics by 1,226.4% in the 3rd quarter. Quest Partners LLC now owns 21,117 shares of the company’s stock valued at $539,000 after acquiring an additional 19,525 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ELVN has been the subject of several recent analyst reports. Robert W. Baird upped their price objective on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, November 15th. BTIG Research assumed coverage on shares of Enliven Therapeutics in a research report on Friday, December 13th. They set a “buy” rating and a $42.00 target price for the company. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $38.25.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.